Page 75 - 《中国药房》2023年14期

M I，et al. Global burden of oesophageal and gastric can‐ 美曲塞一线治疗晚期非鳞状非小细胞肺癌患者的成本-
cer by histology and subsite in 2018[J]. Gut，2020，69（9）： 效果分析[J]. 中国现代应用药学，2021，38（23）：3015-
1564-1571. 3020.
[ 5 ] YANG H，WANG K L，LI Y，et al. Local ablative treat‐ [16] ZHANG Q L，WU P，HE X C，et al. Cost-effectiveness
ment improves survival in ESCC patients with specific analysis of camrelizumab vs. placebo added to chemo‐
metastases，2010-2016：a population-based SEER analysis therapy as first-line therapy for advanced or metastatic
[J]. Front Oncol，2022，12：783752. esophageal squamous cell carcinoma in China[J]. Front
[ 6 ] LI J K，XU J Y，YANG M Y，et al. Therapeutic revolution Oncol，2021，11：790373.
for inoperable stage Ⅲ non-small cell lung cancer in the [17] 国家统计局 . 中华人民共和国 2022 年国民经济和社会
immune era[J]. Cancer Biol Med，2022，19（5）：569-572. 发展统计公报[EB/OL].（2023-02-28）[2023-03-17]. http：//
[ 7 ] SONG Y，ZHANG B，XIN D，et al. First-line serplulimab www. stats. gov. cn/sj/zxfb/202302/t20230228_1919011.
or placebo plus chemotherapy in PD-L1-positive esopha‐ html.
geal squamous cell carcinoma：a randomized，double- [18] MARGUET S，ADENIS A，DELAINE-CLISANT S，et al.
blind phase 3 trial[J]. Nat Med，2023，29（2）：473-482. Cost-utility analysis of continuation versus discontinua‐
[ 8 ] LIU L L，WANG L，CHEN L，et al. Cost-effectiveness of tion of first-line chemotherapy in patients with metastatic
sintilimab plus chemotherapy versus chemotherapy alone squamous-cell esophageal cancer：economic evaluation
as first-line treatment of locally advanced or metastatic oe‐ alongside the E-DIS trial[J]. Value Health，2021，24（5）：
sophageal squamous cell carcinoma[J]. Front Immunol， 676-682.
2023，14：1092385. [19] CAI H F，XU B H，LI N，et al. Cost-effectiveness analysis
[ 9 ] 刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国 of camrelizumab versus chemotherapy as second-line
市场出版社，2020：27-46. treatment of advanced or metastatic esophageal squamous
[10] GUYOT P，ADES A E，OUWENS M J，et al. Enhanced cell carcinoma[J]. Front Pharmacol，2021，12：732912.
secondary analysis of survival data：reconstructing the [20] BRIGGS A，CLAXTON K，SCULPHER M. Decision
data from published Kaplan-Meier survival curves[J]. modelling for health economic evaluation[J]. Int J Epide‐
BMC Med Res Methodol，2012，12：9. miol，2007，36（2）：476-477.
[11] LI X Y，LI W C，HOU L P. A trial-based cost- [21] ZAFAR S Y，ABERNETHY A P. Financial toxicity，Part
effectiveness analysis of bevacizumab and chemotherapy Ⅰ ：a new name for a growing problem[J]. Oncology，
versus chemotherapy alone for advanced nonsquamous 2013，27（2）：80-81，149.
non-small-cell lung cancer in China[J]. Value Health Reg [22] ZHENG Z W，LIN J R，ZHU H D，et al. Cost-
Issues，2019，18：1-7. effectiveness analysis of pembrolizumab plus chemo‐
[12] LIU Q，LUO X，PENG L B，et al. Cost-effectiveness therapy vs. chemotherapy alone as first-line treatment in
analysis of adding ramucirumab to the first-line erlotinib patients with esophageal squamous cell carcinoma and
treatment for untreated EGFR-mutated metastatic non- PD-L1 CPS of 10 or more[J]. Front Public Health，2022，
small cell lung cancer in China[J]. BMJ Open，2020，10 10：893387.
（11）：e040691. [23] LIU S X，DOU L，WANG K X，et al. Cost-effectiveness
[13] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会 analysis of nivolumab combination therapy in the first-
（CSCO）食管癌诊疗指南2022[M]. 北京：人民卫生出版 line treatment for advanced esophageal squamous-cell car‐
社，2022：17-25. cinoma[J]. Front Oncol，2022，12：899966.
[14] YE Z M，XU Z，ZENG F Y，et al. Cost-effectiveness [24] RUTHERFORD M，LAMBERT P，SWEETING M，et al.
analysis of sintilimab combined with chemotherapy versus Flexible methods for survival analysis TSD[EB/OL].
chemotherapy alone as the first-line treatment for ad‐ （2022-07-08）[2023-04-11]. https：//www.sheffield.ac.uk/
vanced esophageal cancer[J]. Front Pharmacol，2022，13： nice-dsu/tsds/flexible-methods-survival-analysis.
934275. （收稿日期：2023-02-20 修回日期：2023-06-17）
[15] 蔡源益，惠文，高志祥，等. 卡瑞利珠单抗联合卡铂和培 （编辑：孙 冰）

中国药房 2023年第34卷第14期 China Pharmacy 2023 Vol. 34 No. 14 · 1729 ·